VIRP Virbac SA

Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

Virbac : the board of directors announces a capital reduction through cancellation of treasury shares

 


 
 



During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders’ meeting on June 20, 2023, decided to reduce the share capital of Virbac by canceling 67,340 treasury shares. These shares were acquired during 2023 under the share buyback program authorized by the same shareholders’ meeting.



As of today, the share capital of Virbac amounts to €10,448,325, represented by 8,390,660 shares of €1.25, fully paid-up.



Following this capital reduction, the Dick family group holds 50.09% of the share capital of Virbac and 66.20% of its voting rights.



Information on the total number of voting rights and shares, as well as the shareholder structure, will be updated on the company's website .



 

Focusing on animal health, from the beginning

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Press contacts - Agence Libremullenlowe

 



Anne Da Silva Passos - - 28



 

Attachment



EN
13/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Virbac SA

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Virbac : Webcast feedback: H1 ahead of guidance and management confide...

>Confidence and visibility signalled by management - During its webcast, management underscored market share gains and its regular outperformance of the veterinary market. Our key takeaways are:1/ 2024 guidance is maintained (operating margin 2024E:16%) despite H1 results that topped consensus expectations: it seems cautious in our view, as we indicated yesterday morning (see our First Take), but the CFO highlighted weaker growth in H2 and historic seasonality (w...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

Virbac : Feedback webcast : S1 en avance sur la guidance et confiance ...

>Sérénité et visibilité affichée par le management - Lors de son webcast, le management a souligné les gains de parts de marché et sa surperformance régulière du marché vétérinaire. Nous retenons surtout :1/ La guidance 2024 est maintenue (MOP 24e :16%) malgré un S1 meilleure qu’attendu par le consensus : elle nous semble prudente comme indiqué hier matin (relire notre commentaire), mais le CFO a fait valoir une croissance moindre au S2 et la saisonnalité histori...

 PRESS RELEASE

Virbac: erratum short Press release Capital reduction_September 13, 20...

Virbac: erratum short Press release Capital reduction_September 13, 2024 This press release rectifies the version of the press release issued by Virbac on September 13, 2024 at 5:45 pm in order to correct a typing error in the amount of Virbac's new share capital. The share capital of Virbac amounts now to €10,488,325 and not €10,448,325 as announced. Focusing on animal health, from the beginningAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch